Scholarlink

<p>An integrated three-step artificial-intelligence (AI) workflow was developed to accelerate the design of a CXCR4-targeted, dual-drug nanocarrier for colorectal cancer therapy. The workflow combined AI-based drug synergy prediction, peptide ligand discovery, and formulation optimization to create a core-shell nanocarrier consisting of a mesoporous silica core coated with a liposomal shell, co-delivering berberine (BBR) and paclitaxel (PTX). The nanocarrier exhibited efficient drug loading, sustained release, and selective uptake by CXCR4-positive cancer cells. In vitro, it synergistically inhibited cancer proliferation and migration, while in vivo it produced pronounced tumor regression and reversal of tumor-associated splenomegaly without systemic toxicity. These findings demonstrate that AI-guided synergy scouting and modular nanocarrier engineering can yield a receptor-targeted combination therapy with translational potential for next-generation cancer treatment.&#xa0;</p> Graphical abstract <p>AI-guided, CXCR4-targeted liposome-mesoporous silica nanocarriers co-load berberine and paclitaxel, sustaining dual release and markedly suppressing tumor growth without systemic toxicity.</p> <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

AI-guided design of a CXCR4-targeted core-shell nanocarrier for co-delivery of berberine/paclitaxel in cancer therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月22日

查看全文
  • Yeonwoo Jang,
  • Amal Babu,
  • Sahil Chahal,
  • Arathy Vasukutty,
  • James J. Moon,
  • In-Kyu Park,
  • Hansoo Park

摘要

An integrated three-step artificial-intelligence (AI) workflow was developed to accelerate the design of a CXCR4-targeted, dual-drug nanocarrier for colorectal cancer therapy. The workflow combined AI-based drug synergy prediction, peptide ligand discovery, and formulation optimization to create a core-shell nanocarrier consisting of a mesoporous silica core coated with a liposomal shell, co-delivering berberine (BBR) and paclitaxel (PTX). The nanocarrier exhibited efficient drug loading, sustained release, and selective uptake by CXCR4-positive cancer cells. In vitro, it synergistically inhibited cancer proliferation and migration, while in vivo it produced pronounced tumor regression and reversal of tumor-associated splenomegaly without systemic toxicity. These findings demonstrate that AI-guided synergy scouting and modular nanocarrier engineering can yield a receptor-targeted combination therapy with translational potential for next-generation cancer treatment. 

Graphical abstract

AI-guided, CXCR4-targeted liposome-mesoporous silica nanocarriers co-load berberine and paclitaxel, sustaining dual release and markedly suppressing tumor growth without systemic toxicity.